Advertisement


Marcin R. Dzienis, MBBS, on Update on Pembrolizumab, Carboplatin, and Paclitaxel in HNSCC

2024 Multidisciplinary Head and Neck Cancers Symposium

Advertisement

Marcin R. Dzienis, MBBS, of Australia’s Gold Coast University Hospital, discusses the final analysis of KEYNOTE-B10, a phase IV study in which patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) received a first-line combination regimen of pembrolizumab plus carboplatin and paclitaxel. The regimen demonstrated durable antitumor activity, irrespective of patients’ PD-L1 status (Abstract 3).



Related Videos

Head and Neck Cancer

Nabil F. Saba, MD, on Head and Neck Cancer: Long-Term Survival Findings With Pembrolizumab and Cabozantinib

Nabil F. Saba, MD, of Emory University, discusses study findings on 2-year survival rates in patients with recurrent metastatic head and neck squamous cell carcinoma who received pembrolizumab plus cabozantinib. The progression-free survival rate of 32% and the overall survival rate of 55% suggest a durable clinical activity of this combination therapy (Abstract 2).

Head and Neck Cancer

Dan P. Zandberg, MD, on Personalized Immunotherapy for HNSCC: Progress Report

Dan P. Zandberg, MD, of UPMC Hillman Cancer Center, discusses study results showing that, although efficacy was low with both nivolumab plus ipilimumab and nivolumab plus relatlimab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC), selected patients had a numerically higher disease control rate, with a longer duration of stable disease (Abstract 4).

Head and Neck Cancer

Evan M. Graboyes, MD, MPH, on Addressing Body Image Distress: Critical Care for Head and Neck Cancer Survivors

Evan M. Graboyes, MD, MPH, of the Medical University of South Carolina, discusses body image distress, a source of significant morbidity among head and neck cancer survivors. He recommends strategies to identify this side effect, the evidence for how best to treat, and best practices to help patients heal emotionally as well as physically.

Head and Neck Cancer

Nabil F. Saba, MD, on Preventing Radiation-Induced Mucositis in Patients With Squamous Cell Carcinoma of the Head and Neck

Nabil F. Saba, MD, of Emory University, discusses phase II study results suggesting parenteral administration of TK-90 may be an effective strategy for preventing radiation-induced oral mucositis in patients with squamous cell carcinoma of the head and neck (Abstract 10).

Head and Neck Cancer

Samuel Regan, MD, and Benjamin Rosen, PhD, on De-escalating Radiotherapy for HPV-Related Oropharyngeal Cancer

Samuel Regan, MD, and Benjamin Rosen, PhD, both of the University of Michigan, discuss results from a phase II trial showing the possibility of de-escalating chemoradiation treatment for patients with HPV-related oropharyngeal cancer, based on an FDG-PET imaging biomarker. The data suggest that patients may experience few locoregional recurrences and less toxicity (Abstract 16).

Advertisement

Advertisement




Advertisement